Multiple Myeloma Masterclass Series – Anti-CD38 mAb-based strategies across the myeloma continuum – Wednesday, October 21, 2026 Uncategorized / Sharon Rawet Lederer Open to access this content Multiple Myeloma Masterclass Series – Anti-CD38 mAb-based strategies across the myeloma continuum – Wednesday, October 21, 2026 Read More »
Multiple Myeloma Academy – Journal Club – Cilta-cel in lenalidomide-refractory multiple myeloma (CARTITUDE-4): an updated analysis including overall survival from an open-label, multicentre, randomised, phase 3 trial – Tuesday, March 10, 2026 Uncategorized / Sharon Rawet Lederer Open to access this content Multiple Myeloma Academy – Journal Club – Cilta-cel in lenalidomide-refractory multiple myeloma (CARTITUDE-4): an updated analysis including overall survival from an open-label, multicentre, randomised, phase 3 trial – Tuesday, March 10, 2026 Read More »
Multiple Myeloma Academy – Journal Club – Daratumumab‐based quadruplet for patients with extramedullary multiple myeloma: Results from the Phase II prospective EMN19 study – Monday, February 23, 2026 Uncategorized / Sharon Rawet Lederer Open to access this content Multiple Myeloma Academy – Journal Club – Daratumumab‐based quadruplet for patients with extramedullary multiple myeloma: Results from the Phase II prospective EMN19 study – Monday, February 23, 2026 Read More »
Perspectives on Outpatient Delivery of Bispecific T-Cell Engager Therapies for Multiple Myeloma – Monday, June 16, 2025 Uncategorized / Sharon Rawet Lederer Open to access this content Perspectives on Outpatient Delivery of Bispecific T-Cell Engager Therapies for Multiple Myeloma – Monday, June 16, 2025 Read More »
Safety and Efficacy of Elranatamab in Patients with Relapsed and/or Refractory immunoglobulin Light-Chain Amyloidosis – Tuesday, October 14, 2025 Uncategorized / Sharon Rawet Lederer Open to access this content Safety and Efficacy of Elranatamab in Patients with Relapsed and/or Refractory immunoglobulin Light-Chain Amyloidosis – Tuesday, October 14, 2025 Read More »
Using Mass Spectrometry Assays in Multiple Myeloma: Where Do We Stand? – Tuesday, April 22, 2025 Uncategorized / Sharon Rawet Lederer Open to access this content Using Mass Spectrometry Assays in Multiple Myeloma: Where Do We Stand? – Tuesday, April 22, 2025 Read More »
Highlights from IMS 2025: A Focus on CELMoDs – Monday, October 20, 2025 Uncategorized / Sharon Rawet Lederer Open to access this content Highlights from IMS 2025: A Focus on CELMoDs – Monday, October 20, 2025 Read More »
Multiple Myeloma Academy – Educating Patients for Better Outcomes – Monday, November 24, 2025 Uncategorized / Sharon Rawet Lederer Open to access this content Multiple Myeloma Academy – Educating Patients for Better Outcomes – Monday, November 24, 2025 Read More »
Multiple Myeloma Academy – Bispecific Antibodies in Multiple Myeloma: Practical Strategies for Safe and Effective Delivery – Thursday, November 20, 2025 Uncategorized / Sharon Rawet Lederer Open to access this content Multiple Myeloma Academy – Bispecific Antibodies in Multiple Myeloma: Practical Strategies for Safe and Effective Delivery – Thursday, November 20, 2025 Read More »
Multiple Myeloma Academy – COMy 2025 – From Thalidomide to CELMoDs: A Clinical Journey – Monday, August 25, 2025 Uncategorized / Sharon Rawet Lederer Open to access this content Multiple Myeloma Academy – COMy 2025 – From Thalidomide to CELMoDs: A Clinical Journey – Monday, August 25, 2025 Read More »
